Available Until 12/31/2023
VIEW CART

Rare Disease Spotlight: IgA Nephropathy Treatment Update

This independent educational program is supported by a grant from Calliditas Therapeutics AB.



Course Description:

Immunoglobulin A Nephropathy (IgAN) is an autoimmune, rare disease and prominent cause of chronic kidney disease and renal failure. More recent initiatives are aimed to better understand the pathogenesis of IgAN, these concepts involve genetic, environmental, multi-factorial, and newer insights indicating links to intestinal immunity abnormalities. Emerging treatment focuses for IgAN management and prevention of end stage renal disease includes disease targeted mechanisms and drug delivery to minimize exposure to traditional treatment toxicities.

Faculty for this session will provide an overview of the new and emerging IgA nephropathy therapies, with a focus on mechanism of action, safety, and efficacy, as well as patient advocacy considerations for access to these therapies, so managed care professionals are able to align formulary decisions with the evolving treatment landscape and patients’ needs.


Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Review the pathogenesis, chronic progression, and complications of IgA nephropathy in relation to available treatment options.
  2. Differentiate new and emerging IgA nephropathy therapies based on guideline recommendations, mechanism of action, efficacy, and safety profiles.
  3. Discuss managed care and patient advocacy considerations impacting access to care and treatment advances for IgA nephropathy.

Faculty(s)

Gisela Delgado

Dir of Brand + Creative | IgAN Patient

IgA Nephropathy Foundation

Jersey City, NJ

Katie Purnell

Senior Pharmacist

Highmark Inc.

Pittsburgh, PA

Arun Rajasekaran, MD, FACP, FASN, FNKF

Clinical Instructor - Nephrology

University of Alabama at Birmingham

Birmingham, AL


Moderator(s)

John Barrett, RPh, MBA

VP- Account Management and Business Development

PerformRx



Accreditation:

The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN:0233-0000-22-020-H01-P • Activity Type: Knowledge-Based
Contact Hours: 1.25
Release Date: March 31, 2022 •  Expiration Date: December 31, 2023
Activity Fee: Free for Members and Non-Members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2022. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities



Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-22-020-H01-P 1.25 Contact Hours March 31, 2022 - December 31, 2023